Autopsy report · NCT03333317
A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus
Cause of deathFunding or business
“Sponsor Decision”
Life of this trial
- Registered 1 month before it started.
- Ran for about 4 months before it stopped.
- 7 participants enrolled.
- Results were posted on the registry 1 year 8 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Industry
- Conditions
- Respiratory Syncytial Viruses
- Interventions
- Lumicitabine; Placebo
- Participants
- 7
- Sites
- 29
- Countries
- Belgium, Canada, Hungary, Japan, Poland, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.